Menu
Login

Report Library

All Reports
Post-AAIC KOL Interview

August 06, 2014

BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

KOL Highlights

  • Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial. (Genentech/Roche)
  • Solanezumab EXPEDITION 3 study is iffy, but KOL believes Eli Lilly is learning from trials and is in it for the long haul (LLY) with a BACE inhibitor and earlier stage compounds in its pipeline.
  • TOMMORROW is enrolling faster than expected, and the trial will likely include more sophisticated pharmacogenetic analysis in addition to the prespecified stratification algorithm. (Takeda)
  • KOL expects results from BACE inhibitors to be the most capable of proving or disproving the amyloid hypothesis (MRK) and thinks the rationale behind combining a BACE inhibitor and an amyloid beta antibody is sound. (NVS)
  • More data is necessary to determine efficacy of pimavanserin in Alzheimer’s disease psychosis. (ACAD)
  • Data from sub 40-mg citalopram showed efficacy in AD agitation. (ACT)
  • More work on blood-based assays to decrease the barrier to entry trials (puncture discomfort) is necessary.

To purchase the full Post-AAIC KOL Insight Interview, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
Disease Group Covered: Neurology
Indications Covered: Guillain-Barré Syndrome
Ischemic Stroke
Post-Traumatic Stress Disorder (PTSD)
Premenstrual Dysphoric Disorder (PMDD)
Sleep Apnea
Smoking Cessation
Substance Use Disorder

 Additional Resources: